[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tongji Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":659},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,161,0,25,[9,44,78,100,125,156,185,210,236,262,287,308,326,348,368,390,422,446,465,494,521,555,580,604,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651058","phase-ibii-study-of-sys6020-in-relapsingrefractory-multiple-sclerosis-100651058",false,"NCT07756268","Phase Ib\u002FII Study of SYS6020 in Relapsing\u002FRefractory Multiple Sclerosis","A Phase Ib\u002FII Clinical Study to Evaluate the Safety and Efficacy of SYS6020 Injection in Patients With Relapsing\u002FRefractory Multiple Sclerosis","Inclusion Criteria:\n\n* 1\\. Male or female participants aged 18-65 years at the time of signing informed consent.\n\n  2\\. Diagnosis of progressive multiple sclerosis (primary progressive MS \\[PPMS\\] or secondary progressive MS \\[SPMS\\]) or relapsing multiple sclerosis (RMS) according to the 2024 McDonald criteria.\n\n  3\\. Inadequate response to at least one disease-modifying therapy (DMT) administered for ≥6 months:\n  1. For progressive MS: evidence of worsening disability, such as an increased Expanded Disability Status Scale (EDSS) score.\n  2. For RMS: at least one of the following:\n\n  i. ≥2 relapses within 2 years before screening; ii. ≥1 relapse within 1 year before screening; or iii. Gadolinium-enhancing lesions on MRI within 1 year before screening. 4. Positive cerebrospinal fluid oligoclonal bands or an elevated immunoglobulin G index, documented previously or during screening.\n\n  5\\. Typical MS lesions on brain and\u002For spinal cord MRI, documented previously or during screening.\n\n  6\\. Screening EDSS score of 3.0-7.0. 7. Adequate baseline organ function, including:\n  1. Absolute lymphocyte count ≥0.3 × 10⁹\u002FL, absolute neutrophil count ≥1.0 × 10⁹\u002FL, platelet count ≥50 × 10⁹\u002FL, and hemoglobin ≥80 g\u002FL, without red blood cell or platelet transfusion or colony-stimulating factor within 7 days before testing;\n  2. Total bilirubin ≤2 × upper limit of normal (ULN), and alanine aminotransferase and aspartate aminotransferase ≤3 × ULN;\n  3. Serum creatinine ≤1.5 × ULN and creatinine clearance ≥40 mL\u002Fmin by the Cockcroft-Gault formula;\n  4. Activated partial thromboplastin time and international normalized ratio ≤1.5 × ULN;\n  5. Oxygen saturation ≥90% on room air;\n  6. Serum potassium ≥3.0 mmol\u002FL and calcium ≥2.0 mmol\u002FL. 8. Participants of reproductive potential must use reliable contraception during the study and for at least 2 years after the last SYS6020 infusion. Women must not donate oocytes and men must not donate sperm for assisted reproduction during this period. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test before leukapheresis.\n\nExclusion Criteria:\n\n* 1\\. Uncontrolled significant chronic disease that, in the investigator's opinion, may increase the participant's risk.\n\n  2\\. Another autoimmune disease requiring systemic treatment, except adequately treated autoimmune thyroid disease with stable treatment and normal thyroid function.\n\n  3\\. History of primary immunodeficiency, organ transplantation, or hematopoietic stem cell\u002Fbone marrow transplantation, or planned transplantation during the study.\n\n  4\\. Current psychotic disorder. 5. Suicidal ideation within 6 months before informed consent, suicidal behavior within 12 months before informed consent, or a significant suicide risk in the investigator's opinion.\n\n  6\\. Alcohol or drug abuse\u002Fdependence likely to impair study compliance. 7. Stroke, transient ischemic attack, or another active central nervous system disorder unrelated to neuroimmunological disease within 6 months before enrollment.\n\n  8\\. Significant cardiovascular disease, including:\n  1. Clinically significant ventricular arrhythmia, second- or third-degree atrioventricular block, or another serious rhythm\u002Fconduction disorder;\n  2. Resting QT interval corrected using Fridericia's formula \\>450 msec for men or \\>470 msec for women;\n  3. Acute coronary syndrome, congestive heart failure, or another Grade ≥3 cardiovascular event within 6 months before first administration;\n  4. Left ventricular ejection fraction \\\u003C50%;\n  5. Risk factors for QT prolongation or arrhythmia, including heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or use of QT-prolonging medications;\n  6. Poorly controlled hypertension, defined as systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg.\n\n     9\\. Major surgery or invasive intervention within 4 weeks before leukapheresis, or planned systemic or local tumor resection during the study.\n\n     10\\. Grade ≥2 bleeding within 30 days before screening or a need for continuous long-term anticoagulant therapy.\n\n     11\\. Active malignancy or history of malignancy, except:\n\n  \u003C!-- -->\n\n  1. Curatively treated basal cell carcinoma, localized cutaneous squamous cell carcinoma, or cervical carcinoma in situ completed \\>12 months before screening; or\n  2. Other malignancies with curative treatment completed ≥5 years before screening. 12. Severe recurrent infections or any active infection that may interfere with study participation.\n\n     13\\. Any of the following viral hepatitis findings:\n\n  \u003C!-- -->\n\n  1. Positive hepatitis B surface antigen;\n  2. Positive hepatitis B core antibody with hepatitis B virus DNA above the lower limit of quantification or 1000 copies\u002FmL (500 IU\u002FmL), whichever is lower;\n  3. Positive hepatitis C virus antibody with hepatitis C virus RNA above the lower limit of quantification or 1000 copies\u002FmL, whichever is lower.\n\n     (Participants with detectable hepatitis B virus DNA or hepatitis C virus RNA within 6 months before screening who subsequently became undetectable after antiviral treatment are also excluded.) 14. History of human immunodeficiency virus infection or positive HIV test at screening.\n\n     15\\. Inability or unwillingness to receive investigator-required prophylaxis against Pneumocystis jirovecii, herpes simplex virus, or herpes zoster; or a positive confirmatory syphilis test.\n\n     16\\. Positive human T-cell lymphotropic virus type 1\u002F2 antibody, cytomegalovirus immunoglobulin M, or Epstein-Barr virus immunoglobulin M.\n\n     17\\. Active bacterial, fungal, or viral infection requiring intravenous antimicrobial therapy within 2 weeks before leukapheresis, or another infection considered clinically relevant by the investigator. Prophylactic antimicrobial treatment without clinical evidence of active infection is permitted.\n\n     18\\. Receipt of a live vaccine within 4 weeks before leukapheresis or planned live vaccination during the study. Messenger RNA vaccines are not considered live vaccines.\n\n     19\\. Previous or active tuberculosis infection or a positive T-SPOT test. 20. Previous CAR-T-cell therapy other than SYS6020 or previous gene therapy. 21. Renal replacement therapy within 3 months before screening or anticipated need for renal replacement therapy during the study.\n\n     22\\. Intravenous immunoglobulin, plasma exchange, plasmapheresis, or hemodialysis within 1 month before leukapheresis.\n\n     23\\. Prednisone ≥20 mg\u002Fday, or equivalent corticosteroid dose, within 7 days before leukapheresis.\n\n     24\\. Calcineurin inhibitors, such as tacrolimus or cyclosporine, or cyclophosphamide within 3 weeks before leukapheresis.\n\n     25\\. Receipt of an investigational product within 4 weeks before screening, unless at least 5 half-lives have passed since last dose, or concurrent participation in another interventional clinical study. Observational studies and follow-up periods of completed interventional studies are permitted.\n\n     26\\. Known allergy, hypersensitivity, intolerance, or contraindication to SYS6020 or its components, including dextran 40; to study-related medications such as acetaminophen or tocilizumab; to beta-lactam antibiotics; or a history of severe allergic reactions.\n\n     27\\. Other drug allergies suggesting an allergic predisposition in the investigator's opinion, or a positive dextran 40 skin test at screening.\n\n     28\\. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.","ALL","18 Years","65 Years",{"count":7,"type":21},"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This trial is an investigator-initiated, single-arm, open-label Phase Ib\u002FII study to observe the safety, tolerability, PK\u002FPD characteristics, immunogenicity, and the efficacy of SYS6020 injection in participants with relapsed\u002Frefractory multiple sclerosis. The study plans to enroll participants with progressive or relapsing multiple sclerosis.\n\nThe recommended dosing regimen is as follows: a single administration dose of 45×10\\^6 CAR-T cells\u002Fkg (allowing a fluctuation of ±20%), administered once a week for 6 consecutive doses.\n\nTo ensure participant safety, this study will establish a Safety Monitoring Committee (SMC). A staggered enrollment and dosing strategy will be adopted in the early stage. Two early safety evaluation will be established (after the first 3 enrolled participants complete their first 3 infusions of SYS6020, and after the first 3 enrolled participants complete their first 6 infusions of SYS6020) for comprehensive assessment.\n\nThe study plans to enroll 10-15 participants. Once the enrollment of 10-15 participants is complete, a comprehensive assessment may be conducted based on the actual progress of the study and combined with existing data. This will fully evaluate the safety, preliminary efficacy, and PK\u002FPD\u002FADA data of the enrolled participants. If the overall safety of the participants is manageable, preliminary efficacy shows a positive trend, and there are value and necessity for further exploration, expanding the number of participants may be considered (up to a maximum of 25 participants in total).",[28],"Multiple Sclerosis",[30],"SYS6020, BCMA, Autologous CAR-T Cell Therapy, mRNA CAR-T, Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","NOT_YET_RECRUITING","2026-08-05",{"date":34,"type":35},"2026-08-10","ACTUAL",{"date":37,"type":21},"2026-09-16",{"date":39,"type":21},"2029-02-07",{"name":41,"class":42},"Tongji Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100650787","nerve-block-and-perioperative-myocardial-injury-in-elderly-hip-fracture-100650787","NCT07751146","Nerve Block and Perioperative Myocardial Injury in Elderly Hip Fracture","Effect of Single-Injection Peripheral Nerve Block on Perioperative Myocardial Injury in Elderly Patients Undergoing Delayed Hip Fracture Surgery: A Single-Center Retrospective Cohort Study","PNB-CARD","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Radiological evidence of non-pathological hip fractures (femoral neck, intertrochanteric or subtrochanteric fractures)\n* Time from injury to surgery \\> 48 hours\n* Underwent general anesthesia or intraspinal anesthesia\n* Had at least one troponin I\u002FT test result during preoperative or postoperative hospitalization\n\nExclusion Criteria:\n\n* Preoperative presence of acute myocardial infarction (onset \\\u003C 7 days), acute heart failure or sepsis\n* Multiple fractures or concurrent surgeries at other sites\n* Neuroblock as the sole anesthesia method\n* Continuous nerve block or epidural analgesia\n* Severe lack of key variables",{"count":53,"type":21},500,"OBSERVATIONAL","This single-center, retrospective cohort study evaluates whether a single preoperative peripheral nerve block can reduce the risk of perioperative myocardial injury in elderly patients undergoing delayed hip fracture surgery, defined as surgery performed more than 48 hours after injury.\n\nHip fracture is a serious and common injury in older adults worldwide. When surgery cannot be performed within the recommended 48-hour window, patients face a much higher risk of heart muscle damage (myocardial injury), which is strongly linked to increased complications and death. Peripheral nerve blocks are a standard, safe method for pain control in hip fracture care, but their potential protective effect on the heart has not been specifically studied in patients with delayed surgery.\n\nThis study will review medical records of patients aged 65 years and older who received hip fracture surgery at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, between January 1, 2019 and December 31, 2025, with time from injury to surgery longer than 48 hours. Patients who received a single peripheral nerve block before surgery will be compared with patients who did not receive any peripheral nerve block.\n\nThe main measure of the study is the rate of myocardial injury during hospital stay, detected by elevated troponin levels in routine blood tests. The study will also examine new-onset myocardial injury within 72 hours after surgery, major heart-related adverse events and all-cause death within 30 days after surgery, length of hospital stay, and other common postoperative complications. Researchers will also explore whether the timing of nerve block placement and different block techniques have different heart-protective effects.\n\nThe findings may provide evidence for a simple, safe and practical strategy to reduce heart complications in older hip fracture patients who cannot receive timely surgery, and help clinicians improve perioperative care for this high-risk population.",[57,58,59],"Hip Fracture","Perioperative Myocardial Injury","Myocardial Injury After Noncardiac Surgery",[61,62,63,64,65,66,67,68,69],"Peripheral Nerve Block","Single-injection nerve block","PENG block","Delayed hip fracture surgery","Elderly patients","Troponin","Perioperative cardioprotection","Retrospective cohort study","Fascia iliaca compartment block","2026-08-03",{"date":72,"type":35},"2026-08-07",{"date":74,"type":21},"2026-07-15",{"date":76,"type":21},"2027-07-05",{"name":41,"class":42},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100650282","icg-fluorescence-versus-co-inflation-deflation-for-intersegmental-plane-identification-during-thoracoscopic-segmentectomy-100650282","NCT07745738","ICG Fluorescence Versus CO₂ Inflation-Deflation for Intersegmental Plane Identification During Thoracoscopic Segmentectomy","Comparison of Indocyanine Green Fluorescence and Carbon Dioxide Inflation-Deflation for Intersegmental Plane Identification During Thoracoscopic Segmentectomy: A Prospective Paired Study","Inclusion Criteria:\n\n1. Adults aged 18 to 80 years.\n2. Scheduled to undergo elective thoracoscopic anatomical segmentectomy.\n3. Preoperative thin-section chest CT with three-dimensional reconstruction available for surgical planning.\n4. Lesion considered suitable for anatomical segmentectomy by the thoracic surgery team.\n5. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Known allergy or contraindication to indocyanine green (ICG).\n2. Pregnant or breastfeeding women.\n3. Severe hepatic dysfunction or other conditions contraindicating the use of ICG.\n4. Severe emphysema, bullous lung disease, diffuse pulmonary fibrosis, or other severe pulmonary parenchymal disease expected to interfere with intersegmental plane identification.\n5. Conversion to thoracotomy before completion of both intersegmental plane identification methods.","80 Years",{"count":87,"type":21},50,[89],"NA","Intersegmental plane identification is a critical step in thoracoscopic anatomical segmentectomy because it helps ensure adequate surgical margins while preserving healthy lung tissue. Indocyanine green (ICG) fluorescence imaging and carbon dioxide (CO₂) inflation-deflation are two techniques used to identify the intersegmental plane, but their agreement and clinical applicability have not been adequately evaluated.\n\nThis prospective paired study aims to compare the intersegmental planes identified by ICG fluorescence imaging and the CO₂ inflation-deflation method during thoracoscopic anatomical segmentectomy. In each participant, both techniques will be performed during the same operation, and the identified intersegmental planes will be compared. The findings of this study may provide evidence regarding the agreement and clinical applicability of the two methods for intersegmental plane identification.",[92],"Pulmonary Nodule, Solitary","2026-08-02",{"date":95,"type":35},"2026-08-04",{"date":74,"type":21},{"date":98,"type":21},"2026-09-30",{"name":41,"class":42},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100584542","clinical-evaluation-of-new-biomarkers-for-ischemic-cerebrovascular-disease-100584542","NCT06890702","Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease","A Prospective Observational Cohort Study of Predictive Biomarkers Related With Ischemic Cerebrovascular Disease","Inclusion Criteria:\n\n* Ischemic cerebrovascular disease has been proved by clinical symptoms and imaging examinations,including transient ischemic attack, cerebral ischemic stroke, steal syndrome, chronic cerebral hypoperfusion, ect al.\n* sex and age-matched healthy individuals\n\nExclusion Criteria:\n\n* Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation)\n* With severe systemic disease, are expected to survive \\\u003C 3 months\n* Patients will not able to provide continuous follow-up information",true,"90 Years",{"count":110,"type":21},7000,"The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are:\n\nCan specific biomarkers help in identifying high-risk individuals before disease onset? Can these biomarkers predict disease progression and treatment response? Researchers will compare patients diagnosed with ICVD and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance.\n\nParticipants will:\n\nProvide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis.\n\nUndergo clinical imaging (CT, MRI, PET-CT) and functional assessments. Be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes.\n\nThis study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.",[113,114],"Ischemic Stroke","Ischemic Cerebrovascular Disease","RECRUITING","2026-07-27",{"date":118,"type":35},"2026-07-28",{"date":120,"type":35},"2025-01-01",{"date":122,"type":21},"2038-01-01",{"name":41,"class":42},2,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":134,"conditions":135,"keywords":146,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100554663","biomarkers-in-autoimmune-disease-of-nervous-system-100554663","NCT06502015","Biomarkers in Autoimmune Disease of Nervous System","Biomarkers of Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al.\n* sex and age-matched healthy individuals\n\nExclusion Criteria:\n\n* Known history of primary immunodeficiency (innate or acquired).\n* Patients with severe central nervous system, pulmonary, or other systemic infections.\n* Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome.\n* Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases.\n* Pregnant or lactating women.",{"count":133,"type":21},50000,"Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.",[136,137,28,138,139,140,141,142,143,144,145],"Autoimmune Diseases of the Nervous System","Neuromyelitis Optica Spectrum Disorder","Guillain-Barre Syndrome","Acute Disseminated Encephalomyelitis","Autoimmune Encephalitis","Stiff-Person Syndrome","Myasthenia Gravis","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Idiopathic Inflammatory Myopathies","Autoimmune Diseases",[147,136,148],"Biomarker","Immune cell",{"date":150,"type":35},"2026-07-29",{"date":152,"type":35},"2024-07-31",{"date":154,"type":21},"2027-07",{"name":41,"class":42},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100649361","ai-guided-surveillance-and-curative-salvage-of-recurrence-after-hepatocellular-carcinoma-resection-or-ablation-100649361","NCT07732504","AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation","A Pragmatic, Multicenter, Open-Label, Blinded-Outcome, Parallel-Group Randomized Controlled Trial of AI-Guided Risk-Adaptive Surveillance for Early Detection and Curative-Intent Salvage of Hepatocellular Carcinoma Recurrence After Resection or Thermal Ablation","HCC-AI-RECLAIM","Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent.\n* First diagnosis of hepatocellular carcinoma, confirmed by histopathology for participants undergoing liver resection, or by histopathology or accepted guideline-concordant imaging criteria for participants undergoing thermal ablation.\n* Completion of first curative-intent treatment consisting of either R0 liver resection with microscopically tumor-negative margins or complete radiofrequency or microwave ablation of all known hepatocellular carcinoma.\n* Qualifying multiphasic contrast-enhanced CT or MRI obtained 28 to 56 days after completion of the final curative-intent procedure.\n* Qualifying imaging confirming no viable tumor at the resection bed or ablation site, no new intrahepatic hepatocellular carcinoma, and no macrovascular invasion, regional nodal disease, or extrahepatic metastasis.\n* No unresolved lesion requiring immediate diagnostic evaluation or treatment at the time of randomization.\n* Randomization within 14 days after the qualifying post-treatment imaging assessment and before the first protocol-scheduled surveillance examination.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Child-Pugh class A liver function.\n* Medically fit for at least one protocol-defined curative-intent salvage treatment should an anatomically amenable recurrence be detected.\n* Able to undergo repeated protocol-required multiphasic contrast-enhanced CT or MRI examinations.\n* Availability of the minimum mandatory baseline data elements required to generate an output from the locked artificial intelligence system.\n* Able and willing to comply with trial procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Any previous episode of hepatocellular carcinoma or previous hepatocellular carcinoma-directed treatment before the current index diagnosis.\n* Microscopically or macroscopically positive surgical margins (R1 or R2 resection).\n* Residual viable tumor after thermal ablation.\n* Any radiological evidence of residual, recurrent, nodal, or metastatic hepatocellular carcinoma at screening.\n* Macrovascular invasion, regional lymph-node metastasis, or extrahepatic metastasis associated with the index hepatocellular carcinoma.\n* Index treatment involving liver transplantation, combined resection and ablation, transarterial therapy, radiotherapy, systemic anticancer therapy, or another hepatocellular carcinoma-directed treatment other than the qualifying R0 resection or complete radiofrequency or microwave ablation.\n* Previous liver transplantation, active placement on a liver-transplant waiting list, or planned liver transplantation in the absence of documented recurrent hepatocellular carcinoma.\n* Planned or ongoing adjuvant antineoplastic treatment intended to reduce hepatocellular carcinoma recurrence after the qualifying procedure. Guideline-concordant antiviral treatment and management of the underlying liver disease are permitted.\n* Concurrent participation in another interventional study expected to affect hepatocellular carcinoma recurrence, survival, surveillance intensity, or eligibility for curative-intent salvage treatment.\n* Combined hepatocellular-cholangiocarcinoma or another non-hepatocellular primary hepatic malignancy.\n* A permanent medical contraindication that would preclude all protocol-defined curative-intent salvage treatment options.\n* Inability to undergo any protocol-permitted contrast-enhanced CT or MRI modality because of contraindication to all available imaging and contrast options.\n* Active malignancy other than hepatocellular carcinoma that requires anticancer treatment or is expected to materially interfere with survival, surveillance adherence, or outcome assessment during the primary 24-month follow-up period.\n* Uncontrolled hepatic decompensation, including refractory ascites or clinically significant hepatic encephalopathy.\n* Pregnancy at the time of randomization.\n* Inability or unwillingness to provide informed consent or comply with protocol-specified follow-up.",{"count":165,"type":21},2000,[89],"Hepatocellular carcinoma, the most common type of primary liver cancer, can recur after liver resection or thermal ablation performed with curative intent. Follow-up imaging is commonly scheduled at fixed intervals, although the risk of recurrence differs among patients and may change over time. This study will test whether a locked artificial intelligence system can use routinely collected clinical, laboratory, and imaging information to recommend when the next surveillance scan should occur.\n\nAdults with no radiological evidence of viable hepatocellular carcinoma after microscopically margin-negative liver resection or complete radiofrequency or microwave ablation will be randomly assigned in a 1:1 ratio to artificial intelligence-guided risk-adapted surveillance or fixed-interval surveillance. In the artificial intelligence-guided group, participants classified as having high, intermediate, or low current recurrence risk will generally undergo the next protocol-scheduled contrast-enhanced imaging examination after 3, 4, or 6 months, respectively. Participants in the control group will undergo protocol-scheduled imaging every 4 months. The risk thresholds are designed so that the expected total number of protocol-scheduled imaging examinations is approximately comparable between the two groups over 24 months.\n\nThe artificial intelligence system provides surveillance recommendations only. It does not diagnose recurrence, determine eligibility for liver transplantation, or select anticancer treatment. Clinically indicated examinations may be performed at any time in either group. When recurrence is confirmed, participants in both groups will undergo the same protocol-defined multidisciplinary evaluation, and potentially curative-intent treatment may be considered when clinically appropriate.\n\nThe primary purpose is to determine whether artificial intelligence-guided surveillance increases the probability of being alive at 24 months without having a recurrence that is no longer amenable to protocol-defined curative-intent treatment. The study evaluates the timing and allocation of surveillance rather than an adjuvant anticancer treatment and is not intended to prevent the biological occurrence of recurrence.",[169],"Hepatocellular Carcinoma (HCC)",[171,172,173,174,175,176,177],"Artificial Intelligence","Risk-Adapted Surveillance","Recurrence Surveillance","Early Detection of Recurrence","Clinical Decision Support","Liver Resection","Radiofrequency Ablation","2026-07-23",{"date":150,"type":35},{"date":181,"type":21},"2026-10-01",{"date":183,"type":21},"2030-12-31",{"name":41,"class":42},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":43},"100648996","ai-guided-first-line-immunotherapy-selection-in-unresectable-hepatocellular-carcinoma-100648996","NCT07729618","AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma","A Multicenter, Parallel-Group, Cluster-Randomized Controlled Trial Evaluating an Artificial Intelligence Clinical Decision Support System for Selection of First-Line Immune Checkpoint Inhibitor-Based Therapy in Unresectable Hepatocellular Carcinoma","HCC-AI-SELECT","Inclusion Criteria:\n\n* Age 18 years or older.\n* Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed using accepted noninvasive radiologic criteria.\n* Unresectable hepatocellular carcinoma for which first-line systemic therapy is indicated, including Barcelona Clinic Liver Cancer stage B disease that is unsuitable for or no longer benefiting from locoregional therapy, or stage C disease.\n* No prior systemic anticancer therapy for unresectable hepatocellular carcinoma.\n* Child-Pugh class A liver function.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Eligible and intended to receive at least one protocol-specified, guideline-concordant immune checkpoint inhibitor-based first-line regimen, as determined by the treating clinician before exposure to the study AI recommendation.\n* Eligibility confirmed and prospective participant registration completed before the final first-line treatment regimen is selected.\n* Baseline contrast-enhanced computed tomography or magnetic resonance imaging suitable for assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 is available before initiation of first-line systemic therapy.\n* Required pretreatment clinical data are available within the protocol-specified assessment windows.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known combined hepatocellular-cholangiocarcinoma or another primary liver malignancy other than hepatocellular carcinoma.\n* A contraindication or clinical condition that makes all protocol-specified immune checkpoint inhibitor-based first-line regimens inappropriate according to applicable prescribing information and routine clinical practice.\n* Initiation of systemic therapy or completion of the final first-line regimen decision before prospective participant registration.\n* Exposure of the treating clinical team to the participant-specific AI recommendation before confirmation of eligibility and registration.\n* Concurrent anticancer treatment for another malignancy that would materially interfere with treatment selection or study outcome assessment.\n* Planned participation in another interventional study that dictates first-line systemic treatment or would interfere with study outcome assessment.\n* Inability to undergo protocol-required tumor imaging or follow-up assessments.",{"count":194,"type":21},1800,[89],"This pragmatic, multicenter, cluster-randomized trial will evaluate whether a locked artificial intelligence (AI) clinical decision-support system can improve outcomes by helping multidisciplinary teams select first-line immune checkpoint inhibitor (ICI)-based systemic treatment for adults with unresectable hepatocellular carcinoma (HCC).\n\nTwenty-six hospitals or independent HCC multidisciplinary teams will be randomly assigned in a 1:1 ratio to AI-assisted treatment selection or usual-care treatment selection. Approximately 1,800 participants will be enrolled. Eligible participants must already be considered suitable for first-line ICI-based systemic therapy; the study does not compare immunotherapy with no immunotherapy.\n\nAt AI-assisted sites, the system will use prespecified pretreatment information to estimate and compare expected outcomes across clinically appropriate, locally available, guideline-concordant ICI-based regimens. The AI output is advisory. Treating clinicians and patients retain responsibility for the final treatment decision, and reasons for not following an AI recommendation will be recorded. At usual-care sites, treatment will be selected through the standard multidisciplinary decision-making process without access to the AI output. Both groups will receive approved standard-of-care treatments.\n\nThe AI model, input definitions, preprocessing pipeline, decision rules, thresholds, and software version will be locked before enrollment of the first participant and will not be retrained or modified using trial outcome data. Both groups will use the same eligibility criteria, patient-registration time point, imaging schedule, follow-up schedule, and outcome definitions.\n\nThe primary outcome is progression-free survival assessed by blinded independent central imaging review. Overall survival is a key secondary outcome. Additional outcomes include tumor response, duration of response, safety, quality of life, treatment delivery, and implementation measures. This trial evaluates the clinical utility of a prespecified AI system rather than developing or optimizing another prediction model.",[198],"Unresectable Hepatocellular Carcinoma",[171,200,201,202,203],"Machine Learning","Clinical Decision Support System","Immune Checkpoint Inhibitors","First-Line Systemic Therapy","2026-07-22",{"date":116,"type":35},{"date":181,"type":21},{"date":208,"type":21},"2029-12-01",{"name":41,"class":42},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":43},"100530900","phase-2-combined-haic-lenvatinib-and-pucotenlimab-as-conversion-therapy-for-unresectable-intrahepatic-cholangiocarcinoma-100530900","NCT06192797","Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","A Phase 2, Open-label, Single Arm Study of Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","CCGLC-013","Inclusion Criteria:\n\n* Histologically confirmed intrahepatic cholangiocarcinoma.\n* Age ≥18 years.\n* ECOG performance status score of 0 or 1.\n* Not suitable for radical surgery (including radical hepatic resection, liver transplantation or ablation) after evaluation by the MDT expert group of treating hepatobiliary cancer. Specifically, any of the following conditions are met：\n\n  1. R0 resection is not feasible.\n  2. in subjects without cirrhosis, the volume of normal liver parenchyma is less than 30% of the total volume, or in patients with cirrhosis, the volume of normal liver parenchyma is less than 40% of the total volume, or ICG-R15\\>15%.\n  3. Number of lesions \\>1.\n* No prior systemic anti-tumor treatment for intrahepatic cholangiocarcinoma before the first dose.\n* According to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V1.1), at least 1 measurable lesion, or a measurable lesion that has clearly progressed (based on RECIST V1.1 criteria) after local treatment.\n* Subjects with portal vein tumor thrombus (PVTT):\n\n  1. Chen's group A and B, or Cheng's type I-III can be enrolled.\n  2. Chen's group C, or Cheng's type IV (superior vena cava tumor thrombus) cannot be enrolled.\n* Subjects with hepatic vein tumor thrombus:\n\n  1. VV1 and VV2 types can be enrolled.\n  2. VV3 type, or Sakamoto type I (inferior vena cava tumor thrombus) can also be enrolled.\n  3. Sakamoto type II (inferior vena cava tumor thrombus extending above the diaphragm), or Sakamoto type III (inferior vena cava tumor thrombus reaching the right atrium) cannot be enrolled.\n* Subjects with oligometastases outside the liver can be enrolled: Oligometastases outside the liver are defined as up to three metastatic lesions in a maximum of two organs, with the largest diameter being 3cm.\n* Child-Pugh score less than or equal to 7.\n* Adequate organ and bone marrow function, with laboratory test values meeting the following requirements within 7 days prior to inclusion (no blood components, cell growth factors, albumin, or other intravenous or subcutaneous corrective treatment drugs are allowed within 14 days prior to obtaining laboratory tests):\n\n  1. Complete blood count: Absolute Neutrophil Count (ANC) ≥1.5×10\\^9\u002FL; Platelet count (PLT) ≥75×10\\^9\u002FL; Hemoglobin (HGB) ≥9.0 g\u002FdL.\n  2. Liver function: Total Bilirubin (TBIL) ≤2×Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤5×ULN; Serum albumin ≥28 g\u002FL; Alkaline Phosphatase (ALP) ≤5×ULN.\n  3. Kidney function: Serum Creatinine (Cr) ≤ 1.5×ULN or Clearance of Creatinine (CCr) ≥50mL\u002Fmin (Cockcroft-Gault formula); Urinalysis shows proteinuria \\\u003C2+; For subjects with baseline urinalysis showing proteinuria ≥2+, a 24-hour urine collection should be performed and 24-hour urinary protein quantification \\\u003C1g.\n  4. Coagulation function: International Normalized Ratio (INR) ≤2.3 or Prothrombin Time (PT) extension ≤6 seconds.\n* Estimated life expectancy of ≥12 weeks.\n* Female subjects of childbearing age or male subjects whose sexual partners are of childbearing age need to take effective contraceptive measures during the entire treatment period and for 6 months after the last medication.\n* Signed written informed consent, and able to comply with the visit and related procedures stipulated in the protocol.\n\nExclusion Criteria:\n\n* Histologically\u002Fcytologically confirmed sarcomatoid intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma, etc.\n* History of hepatic encephalopathy or liver transplantation.\n* Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Patients with only radiologically detected minimal pleural effusion, ascites, or pericardial effusion without symptoms can be included.\n* Acute or chronic active hepatitis B or C infection, with hepatitis B virus (HBV) DNA \\>2000IU\u002Fml or 10\\^4 copies\u002Fml; hepatitis C virus (HCV) RNA \\>10\\^3 copies\u002Fml; co-positive for hepatitis B surface antigen (HbsAg) and anti-HCV antibody. Patients who meet the above criteria after antiviral treatment with nucleoside analogs can be included.\n* Presence of central nervous system metastases.\n* History of esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months. Patients assessed by the investigator to be at high risk of bleeding.\n* Any life-threatening bleeding event within the past 3 months, including those requiring blood transfusion, surgery or local treatment, or continuous drug treatment.\n* History of arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other serious thromboembolic events. Exceptions are made for thrombosis formation related to implanted venous infusion ports or catheters, or superficial vein thrombosis that has stabilized after routine anticoagulation treatment. Preventive use of low-dose low molecular weight heparin (such as enoxaparin 40 mg\u002Fday) is allowed.\n* Continuous use of aspirin (\\>325 mg\u002Fday) or other known platelet function inhibitors such as clopidogrel or ticlopidine for 10 days within 2 weeks prior to the first dose.\n* Uncontrolled hypertension, with systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy.\n* Presence of any toxicity caused by previous treatment that has not recovered to grade 0 or 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0) before the first dose of study treatment (excluding alopecia, non-clinically significant and asymptomatic laboratory abnormalities).\n* Symptomatic congestive heart failure (New York Heart Association class II-IV), left ventricular ejection fraction (LVEF) \\\u003C50% as indicated by echocardiography.\n* Symptomatic or poorly controlled arrhythmia. History of congenital long QT syndrome or corrected QTc \\>500 ms (calculated using the Fridericia formula) at screening.\n* Severe bleeding tendency or coagulation disorder, or currently receiving thrombolytic therapy.\n* History of gastrointestinal perforation and\u002For fistula, intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea within the past 6 months.\n* Received radiotherapy within 3 weeks prior to the first dose of study treatment. For patients who received radiotherapy more than 3 weeks prior to the first dose of study treatment, all of the following conditions must be met for inclusion: no current radiation-related toxicities, no need for corticosteroids, and exclusion of radiation pneumonitis, radiation hepatitis, radiation enteritis, etc.\n* History or current diagnosis of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function, and other lung diseases.\n* Active pulmonary tuberculosis, currently receiving anti-tuberculosis treatment, or received anti-tuberculosis treatment within 1 year prior to the first dose.\n* Infection with human immunodeficiency virus (HIV) (HIV 1\u002F2 antibody positive), known syphilis infection requiring treatment.\n* Active or clinically uncontrolled severe infection. Severe infection within 4 weeks prior to the first dose, including but not limited to hospitalization for complications of infection, sepsis, or severe pneumonia.\n* Active autoimmune disease requiring systemic treatment (such as disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency, etc.) is allowed. History of primary immunodeficiency. Patients with only autoantibody positivity need to be confirmed by the investigator whether there is an autoimmune disease.\n* Use of immunosuppressive drugs within 4 weeks prior to the first dose, excluding intranasal, inhaled, or other local corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10mg\u002Fday prednisone or equivalent doses of other corticosteroids). Temporary use of corticosteroids for the treatment of dyspnea symptoms due to allergies or diseases such as asthma, chronic obstructive pulmonary disease, etc., is allowed.\n* Received a live attenuated vaccine within 4 weeks prior to the first dose or planned to receive one during the study period.\n* Major surgery (craniotomy, thoracotomy, or laparotomy) or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose. Minor surgical procedures or tissue biopsy within 7 days prior to the first dose, excluding venous puncture for the purpose of intravenous infusion, are excluded.\n* Local treatment for hepatocellular carcinoma within 4 weeks prior to the first dose.\n* Use of traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, etc., except for local use to control pleural effusion or ascites, etc.) within 2 weeks prior to the first dose.\n* Uncontrolled\u002Funcorrectable metabolic disorders or other non-malignant neoplastic organ diseases or systemic diseases or secondary reactions to cancer that could result in higher medical risk and\u002For uncertainty in survival evaluation, or the presence of other conditions that, in the judgment of the investigator, make enrollment inappropriate.\n* Diagnosis of other malignancy within 5 years prior to first dose, excluding radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For radically resected carcinoma in situ. If other malignancy was diagnosed more than 5 years prior to dosing, even if the liver lesion meets the EASL-ILCA clinical diagnostic criteria for intrahepatic cholangiocarcinoma, the liver lesion must still be diagnosed pathologically or cytologically and those who are definitively intrahepatic cholangiocarcinoma may be enrolled.\n* Previous treatment with any anti-PD-1 antibody, anti-PD-L1\u002FL2 antibody, anti-CTLA-4 antibody, or other immunotherapy. Previous treatment with targeted therapy against VEGF and\u002For VEGFR, RAF, MEK, PDGFR, FGFR, etc.\n* Known allergy to any component of oxaliplatin, 5-fluorouracil, calcium folinate, lenvatinib, or pucotenlimab; or severe allergic reaction to other monoclonal antibodies in the past.\n* Patients diagnosed with aortic dissection aneurysm, celiac trunk and superior mesenteric artery dissection aneurysm.\n* Received treatment in other clinical trials within 4 weeks prior to the first dose.\n* Pregnant or breastfeeding women.\n* Patients with systemic multiple metastases, portal vein tumor thrombus involving the superior mesenteric vein, inferior vena cava tumor thrombus extending above the diaphragm or reaching the right atrium.\n* Other acute or chronic diseases, mental illnesses, or laboratory test abnormalities that may result in the following outcomes: increased risk associated with study participation or study drug administration, or interference with the interpretation of study results, and other conditions that, in the investigator's judgment, make the patient ineligible to participate in the study.",{"count":219,"type":21},36,[25],"This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.",[223],"Cholangiocarcinoma Non-resectable",[225,226,227,228],"Intrahepatic Cholangiocarcinoma","Pucotenlimab","Lenvatinib","HAIC","2026-07-21",{"date":204,"type":35},{"date":232,"type":35},"2024-06-04",{"date":234,"type":21},"2029-06-30",{"name":41,"class":42},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":43},"100646037","predictors-of-epidural-depth-in-percutaneous-nephrolithotomy-and-model-development-100646037","NCT07697053","Predictors of Epidural Depth in Percutaneous Nephrolithotomy and Model Development","Analysis of Factors Influencing Epidural Depth in Patients Undergoing Percutaneous Nephrolithotomy and Development of a Predictive Model","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Successful epidural puncture and catheter placement using the midline approach\n* Clear documentation of puncture level and puncture depth in the anesthesia record\n\nExclusion Criteria:\n\n* Dural puncture during anesthesia (including those who subsequently had a successful repuncture)\n* Use of the paramedian approach for epidural puncture\n* Uncertain epidural anesthesia effect requiring combined general anesthesia\n* Incomplete clinical data",{"count":244,"type":21},3278,"Accurate estimation of epidural depth is critical for safe epidural anesthesia during percutaneous nephrolithotomy (PCNL). Although various imaging modalities can predict epidural depth, they increase healthcare burden and are not always feasible in emergency or bedside settings. Identifying simple, easily obtainable clinical parameters-such as sex, age, and body mass index (BMI)-for predicting epidural depth has become a research priority. However, systematic investigations specifically targeting the Chinese population remain scarce. This retrospective study aims to identify independent factors influencing epidural depth in PCNL patients and to develop simple, level-specific predictive models for different puncture sites, thereby providing a practical reference for clinical epidural anesthesia.",[247,248],"Epidural Anesthesia","Percutaneous Nephrolithotomy (PCNL)",[250,251,252,253,248],"epidural anesthesia","epidural depth","predictive model","body mass index","2026-07-13",{"date":256,"type":35},"2026-07-16",{"date":258,"type":21},"2026-06-30",{"date":260,"type":21},"2026-08-31",{"name":41,"class":42},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":107,"sex":17,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":43},"100463981","fecal-microbiota-transplantation-as-the-first-line-treatment-in-active-pediatric-crohns-disease-100463981","NCT05321758","Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease","Repeated and Multiple Fecal Microbiota Transplantations Plus Partial Enteral Nutrition as the First-line Treatment in Active Pediatric Crohn's Disease","FMT","Inclusion Criteria:\n\nage of older than 2 years and younger than 16 years with no genetic diseases; newly diagnosed with mild-to-moderate CD ( defined by the PCDAI of \\>10 and ≤40, and SES-CD of \\>3); Subjects with no change in medication or dose at least 1 week prior to transplantation; agree to received regularly colonoscopy\n\nExclusion Criteria:\n\npatients who were treated with corticosteroids, methotrexate, thiopurines, and anti-TNF agents as their first-line treatment","2 Years","16 Years",{"count":87,"type":21},[89],"To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.",[276],"Crohn Disease",[278],"Crohn Disease;fecal microbiota transplantation","2026-07-09",{"date":281,"type":35},"2026-07-10",{"date":283,"type":35},"2020-03-22",{"date":285,"type":21},"2027-06-30",{"name":41,"class":42},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":295,"targetDuration":297,"studyType":54,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":4},"100645994","tdln-guided-lymphadenectomy-after-neoadjuvant-immunochemotherapy-for-escc-100645994","NCT07697898","TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC","Tumor-Draining Lymph Node Preservation-Guided Intraoperative Lymphadenectomy After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Observational Cohort Study","Inclusion Criteria:\n\n* Age 18 to 75 years, regardless of sex.\n* Eastern Cooperative Oncology Group performance status of 0 to 1.\n* Histologically confirmed thoracic esophageal squamous cell carcinoma.\n* Received neoadjuvant immunochemotherapy and considered suitable for curative surgery after multidisciplinary team evaluation.\n* Clinically resectable locally advanced or locally progressive disease without evidence of distant metastasis.\n* Completed preoperative contrast-enhanced computed tomography of the neck, chest, and abdomen. Positron emission tomography-computed tomography and\u002For endoscopic ultrasound may be performed if clinically available.\n* Considered by the investigator to be able to tolerate curative esophagectomy and standard systematic lymphadenectomy.\n\nExclusion Criteria:\n\n* Non-squamous cell carcinoma histology or concurrent primary malignancy requiring treatment.\n* Previous curative surgery for esophageal cancer or previous radiotherapy for the current esophageal lesion.\n* Evidence of distant metastasis, unresectable disease, or considered unsuitable for curative surgery after multidisciplinary team evaluation.\n* Severe autoimmune disease requiring long-term systemic immunosuppressive therapy.\n* Severe cardiac, pulmonary, hepatic, renal, or other major organ dysfunction that prevents surgery or completion of study-related assessments.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study, including poor compliance, inability to complete scheduled follow-up, or inability to provide key study data.","75 Years",{"count":296,"type":21},400,"24 Months","This is a prospective, multicenter, observational cohort study of patients with esophageal squamous cell carcinoma who have received neoadjuvant immunochemotherapy and are scheduled to undergo curative esophagectomy with standard systematic lymphadenectomy.\n\nThe study will not alter the current standard surgical approach. All patients will receive curative esophagectomy and systematic lymph node dissection according to institutional practice. Lymph nodes will be separated and recorded by anatomical station during surgery, followed by station-level pathological assessment. Imaging findings, pathological response, perioperative outcomes, recurrence patterns, disease-free survival, overall survival, and selected immune microenvironment features will be collected and analyzed.\n\nThe purpose of this study is to characterize station-level residual lymph node metastasis risk and immune activity after neoadjuvant immunochemotherapy. The findings may help identify candidate lymph node stations for future research on individualized or lymph node-preserving surgical strategies in esophageal squamous cell carcinoma.",[300],"Esophageal Squamous Cell Carcinoma (ESCC)","2026-07-07",{"date":254,"type":35},{"date":304,"type":21},"2026-07-01",{"date":306,"type":21},"2031-06-30",{"name":41,"class":42},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":43},"100645780","phase-2-neoadjuvant-cardonilizumab-combined-with-neoadjuvant-chemoradiotherapy-can-resect-locally-advanced-esophageal-squamous-cell-carcinoma-100645780","NCT07699185","Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma","Neoadjuvant Cardonilizumab Combined With Chemotherapy Versus Neoadjuvant Concurrent Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter, Open-label, Randomized, Controlled Study","Inclusion Criteria:\n\n* Sign a written informed consent before implementing any procedures related to the trial;\n* Male or female, 18 years old ≤75 years old;\n* Patients with histologically proven ESCC with a pathological stage of cT1N2M0 or cT2-3N0-2M0 according to AJCC Version 8 TNM stage and eligible for R0 surgical resection prior to treatment;\n* Have not received systematic treatment for the current disease, including surgical treatment, anti-tumor chemoradiotherapy\u002Fimmunotherapy, etc.;\n* Patients who agree to radical surgical treatment and are judged by the surgeon to have no surgical contraindications;\n* ECOG score 0-1;\n* Expected survival time \\>6 months;\n* For adequate organ function, subjects must meet the following laboratory criteria:\n* For adequate organ function, subjects must meet the following laboratory criteria:\n\n  1. The absolute value of neutrophil (ANC) ≥1.5x109\u002FL in the past 14 days without the use of granulocyte colony-stimulating factor;\n  2. Platelets ≥100×109\u002FL without blood transfusion in the past 14 days;\n  3. Hemoglobin \\>9g\u002FdL in the last 14 days without blood transfusion or use of erythropoietin;\n  4. Total bilirubin ≤1.5× upper limit of normal (ULN);\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are ≤2.5×ULN\n  6. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml\u002Fmin;\n  7. Good coagulation function, defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;\n  8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;\n  9. The myocardial enzyme profile was within the normal range (if the researcher comprehensively judged that the simple laboratory abnormality was not clinically significant, it was also allowed to be included);\n* For female subjects of reproductive age, a urine or serum pregnancy test should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1) and the results are negative. If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is requested. Women of non-reproductive age were defined as at least one year after menopause or having undergone surgical sterilization or hysterectomy;\n* If there is a risk of conception, all subjects (male or female) are required to use contraception with an annual failure rate of less than 1% for the entire duration of treatment up to 120 days after the last study drug administration (or 180 days after the last chemotherapy drug administration).\n\nExclusion Criteria:\n\n* Diagnosis of other malignant diseases (excluding radical basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and\u002For carcinoma in situ after radical resection) within 1.5 years;\n* Known endoscopic signs of active bleeding;\n* Is currently participating in an interventional clinical study, or has received other investigational drugs or used investigational devices within 4 weeks prior to initial dosing;\n* Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that respond to another stimulus or synergistic inhibition of T cell receptors (including but not limited to CTLA-4, OX-40, CD137, etc.);\n* Received systemic systemic treatment with Chinese patent drugs with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use to control pleural fluid) within 2 weeks before the first administration;\n* An active autoimmune disease requiring systemic treatment (e.g. with disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years prior to first administration. Replacement therapies (such as thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy;\n* Was receiving systemic glucocorticoid therapy (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days prior to the study's initial administration; Note: The use of physiological doses of glucocorticoids (≤10 mg\u002F day of prednisone or equivalent) is permitted;\n* Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n* Known allergy to the drugs used in this study;\n* Has not fully recovered from toxicity and\u002For complications caused by any intervention before starting treatment (i.e., ≤ grade 1 or baseline, excluding weakness or hair loss);\n* Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive);\n* Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greater than the upper limit of normal value in the laboratory of the study center); Note: Hepatitis B subjects who meet the following criteria can also be enrolled:\n\n  1. HBV viral load \\\u003C2500 copies \u002Fml (500 IU\u002Fml) prior to initial dosing, subjects should receive anti-HBV therapy throughout study chemotherapy therapy to avoid viral reactivation\n  2. For subjects with anti-HBC (+), HBsAg (-), anti-HBS (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring of viral reactivation is required\n* Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);\n* Received live vaccine within 30 days prior to the first dose (cycle 1, day 1);\n* Note: It is permissible to receive injectable inactivated virus vaccine against seasonal influenza within 30 days prior to initial administration; However, live attenuated influenza vaccines administered intranasally are not permitted\n* Pregnant or lactating women;\n* The presence of any serious or uncontrolled systemic disease, such as:\n\n  1. The resting electrocardiogram has major abnormal rhythm, conduction or morphology, such as complete left bundle branch block, heart block above Ⅱ degree, ventricular arrhythmia or atrial fibrillation;\n  2. Unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure;\n  3. Any arterial thrombosis, embolism or ischemia occurred within 6 months before treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack;\n  4. Poor blood pressure control (systolic \\> 140 mmHg, diastolic \\> 90 mmHg);\n  5. There is a history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to first administration, or there is currently clinically active interstitial lung disease;\n  6. Active pulmonary tuberculosis;\n  7. There is an active or uncontrolled infection that requires systemic treatment;\n  8. Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;\n  9. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;\n  10. Poor diabetes control (fasting blood glucose (FBG) \\> 10mmol\u002FL);\n  11. Urine routine indicated urine protein ≥++, and confirmed 24-hour urine protein quantity \\> 1.0 g;\n  12. Patients with mental disorders who cannot cooperate with treatment; Evidence of medical history or disease that might interfere with the test results, prevent participants from fully participating in the study, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment The Investigator considers other potential risks unsuitable for participation in the study.",{"count":316,"type":21},336,[25],"This is a multicenter, open-label, randomized, controlled clinical study to compare the efficacy and safety of cardonilizumab combined with neoadjuvant chemotherapy and surgery versus neoadjuvant chemoradiotherapy and surgery in locally advanced ESCC. Subjects were randomly divided into experimental group and control group, the experimental group received neoadjuvant immunotherapy concurrent chemotherapy regimen, the control group received neoadjuvant concurrent chemoradiotherapy regimen, and then received McKeown surgery. The primary outcome measures were complete pathological response (pCR), and the secondary outcome measures were major pathological response (MPR), EFS (event-free survival), OS (overall survival), overall response rate (ORR), decreased pathological stage, R0 resection rate, adverse events (AE), and perioperative complications",[320],"Esophageal Squamous Cell Carcinoma",{"date":254,"type":35},{"date":323,"type":35},"2024-01-29",{"date":304,"type":21},{"name":41,"class":42},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":4},"100646792","patient-specific-3d-model-assisted-preoperative-consultation-for-thoracoscopic-lung-resection-100646792","NCT07686549","Patient-Specific 3D Model-Assisted Preoperative Consultation for Thoracoscopic Lung Resection","Patient-Specific Three-Dimensional Thoracic Anatomical Model-Assisted Preoperative Consultation to Improve Shared Decision-Making in Patients Undergoing Thoracoscopic Lung Resection: A Single-Center Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Scheduled to undergo elective thoracoscopic anatomical lung resection for suspected or confirmed lung tumors, defined as lobectomy or segmentectomy.\n3. The planned operation and relevant alternatives can be reasonably discussed during preoperative consultation by the attending thoracic surgeon.\n4. Clinically stable and able to participate in preoperative consultation.\n5. Able to read, understand, and complete Chinese questionnaires independently or with neutral assistance from research staff.\n6. Able and willing to provide written informed consent. -\n\nExclusion Criteria:\n\n1. Emergency surgery.\n2. Planned wedge resection only, pneumonectomy, extrapleural pneumonectomy, or non-thoracoscopic open surgery at recruitment.\n3. Previous major ipsilateral thoracic surgery that substantially alters thoracic anatomy and may make the generic model misleading.\n4. Known cognitive impairment, severe psychiatric disorder, severe visual impairment, severe hearing impairment, or language barrier that prevents effective participation in consultation or questionnaire completion.\n5. Participation in another interventional study expected to affect preoperative anxiety, patient education, decision-making, or perioperative communication.\n6. Any other condition judged by the investigators to make the patient unsuitable for this study.\n\n   \\-",{"count":334,"type":21},132,[89],"This study is a single-center, cluster randomized controlled trial evaluating whether lung three-dimensional model-assisted preoperative consultation can improve shared decision-making in adult patients undergoing thoracoscopic anatomical lung resection.\n\nSix attending thoracic surgeons will be randomized to provide either three-dimensional model-assisted consultation or usual preoperative consultation. Patients in the intervention group will receive consultation supported by a generic lung three-dimensional model and patient-specific three-dimensional reconstruction data generated from routine preoperative imaging. Patients in the control group will receive usual preoperative consultation according to current clinical practice.\n\nThe primary outcome is patient-perceived shared decision-making measured immediately after consultation using the 9-item Shared Decision-Making Questionnaire. Secondary outcomes include anxiety, disease- and surgery-related knowledge, communication satisfaction, health-related quality of life, decision regret, consultation duration, and postoperative outcomes within 30 days.",[338,339,340,341],"Lung Neoplasms","Thoracoscopic Lung Resection","Shared Decision Making","Preoperative Counseling","2026-07-03",{"date":301,"type":35},{"date":345,"type":21},"2026-08-01",{"date":285,"type":21},{"name":41,"class":42},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":367,"locationsCount":43},"100644820","neoadjuvant-pd-1-inhibitor-plus-sox-chemotherapy-with-or-without-short-course-radiotherapy-for-locally-advanced-upper-gastric-or-gej-adenocarcinoma-100644820","NCT07674342","Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma","A Prospective, Multicenter, Randomized Controlled Study of Neoadjuvant PD-1 Inhibitor Combined With SOX Chemotherapy With or Without Short-Course Radiotherapy (With Omission of Regional Lymph Node Irradiation) for Locally Advanced Upper Gastric or Gastroesophageal Junction Adenocarcinoma","POSIT","Inclusion Criteria:\n\n* The participant voluntarily joins this study, is able to complete the signing of the informed consent form, and demonstrates good compliance.\n* Age 18-75 years (at the time of signing the informed consent), regardless of gender.\n* Adenocarcinoma confirmed by histology and\u002For cytology, diagnosed as locally advanced according to the AJCC 8th edition criteria, with cTNM staged as cT3-4 or N+ M0 based on endoscopic ultrasound or contrast-enhanced CT\u002FMRI, and the patient agrees to receive neoadjuvant therapy; the lesion is assessed by the investigator as resectable or potentially resectable; after MDT evaluation, radical resection is planned with standard D2 lymph node dissection.\n* Primary lesion site restrictions: (1) Adenocarcinoma of the gastroesophageal junction: Siewert type II-III; (2) Upper stomach cancer: the lower edge of the tumor is located within the upper third of the stomach, mainly involving the cardia, fundus, or upper part of the stomach body.\n* Has not previously received systemic treatment for the current disease, including anti-tumor radiotherapy\u002Fchemotherapy or immunotherapy.\n* ECOG score 0-1.\n* Estimated survival period \\>= 6 months.\n* Preoperative chest, abdominal, and pelvic CT, as well as FAPI PET or PET-CT, to rule out distant metastasis.\n* Major organ function is satisfactory and meets the following criteria: (1) Complete blood count (without blood transfusion or use of hematopoietic growth factors within 14 days to correct status): hemoglobin (Hb) \\>=90 g\u002FL; absolute neutrophil count (ANC) \\>=1.5 × 10\\^9\u002FL; platelets (PLT) \\>=80 × 10\\^9\u002FL; (2) Biochemical tests: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C=2.5 × ULN; total bilirubin (TBIL) \\\u003C=1.5 × ULN; serum creatinine (Cr) \\\u003C=1.5 × ULN, or creatinine clearance \\>=60 mL\u002Fmin; (3) Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) \\\u003C=1.5 × ULN; (4) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) \\>=50%.\n* The doctor clinically determines that there is sufficient organ function.\n* Subjects of reproductive potential must use appropriate contraception during the study and for 120 days after the study ends, have a negative serum pregnancy test within 7 days prior to study enrollment, and must not be breastfeeding.\n\nExclusion Criteria:\n\n* Undergo radiotherapy within 4 weeks before enrollment, or radionuclide therapy within 8 weeks.\n* Within 6 months before enrollment: esophageal or gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, fistulas, intestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding.\n* Diagnosis of malignancies other than gastric cancer within 5 years prior to first administration (excluding completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For completely resected carcinoma in situ).\n* Presence of distant metastasis (M1), including but not limited to: peritoneal metastasis (confirmed by imaging or laparoscopy), ascites or positive peritoneal lavage cytology, metastasis to organs such as liver, lung, or bone; cases where imaging suggests metastasis to para-aortic lymph nodes (No.16).\n* Imaging suggests excessive regional lymph node burden: suspicious\u002Fpositive lymph node involvement in \\>=3 anatomical stations; or multiple lymph nodes are fused\u002Fform a cluster (matted nodes); or any lymph node has a short axis \\>=15 mm.\n* The tumor lesion has a serious tendency to bleed (such as the presence of an active deep large ulcer, a history of vomiting blood or black stools within 2 months before signing the informed consent, or a risk of major gastrointestinal bleeding as determined by the investigator), or has received blood transfusion treatment within 4 weeks prior to the study medication.\n* Inability to swallow oral medications, malabsorption syndrome, or other conditions affecting gastrointestinal absorption.\n* Currently participating in interventional clinical research treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to the first administration.\n* Previously received systemic or local anti-tumor treatment for gastric cancer, including curative surgery, chemotherapy, radiotherapy, immunotherapy (such as immune checkpoint inhibitors, agonists, or cell therapy), biological agents, or small molecule targeted drugs.\n* Systemic therapy with traditional Chinese medicine having anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukins, except for local use to control pleural effusion) within 2 weeks prior to the first dose.\n* Active autoimmune disease that required systemic treatment (such as disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years before the first administration. Replacement therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatment.\n* The participant is receiving systemic corticosteroid therapy (excluding nasal, inhaled, or other forms of topical corticosteroids) or any other form of immunosuppressive therapy within the 7 days prior to the first study drug administration; Note: The use of physiological doses of corticosteroids (\\\u003C=10 mg\u002Fday of prednisone or equivalent) is allowed; short courses of corticosteroids are allowed for medically necessary reasons such as chemotherapy-induced nausea, premedication for contrast agent allergy, or other short-term medical needs.\n* Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n* Known allergies to medications used in this study.\n* Peripheral neuropathy \\>= grade 2.\n* Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive).\n* Subjects with active hepatitis B or hepatitis C (HBsAg positive with HBV DNA levels above the upper limit of normal; HCVAb positive with HCV RNA levels above the upper limit of normal (Note: Subjects who are HBV DNA positive may be enrolled if they are willing to undergo full antiviral treatment throughout the study and have already started treatment before enrollment, subject to consultation with an infectious disease specialist).\n* Within 30 days before the first dose (Cycle 1, Day 1), live vaccines were administered; inactivated influenza vaccines for injection against seasonal flu are allowed within 30 days before the first dose; however, intranasal live attenuated influenza vaccines are not allowed.\n* Pregnant or breastfeeding women.\n* Presence of any severe or uncontrollable systemic disease, such as: (1) Significant and symptomatic abnormalities on resting electrocardiogram in rhythm, conduction, or morphology that are difficult to control, such as complete left bundle branch block, second-degree or higher heart conduction block, ventricular arrhythmias, or atrial fibrillation; (2) Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class \\>= 2; (3) Any arterial thrombosis, embolism, or ischemia within 6 months prior to treatment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; (4) Long-term poorly controlled hypertension (systolic blood pressure \\>160 mmHg, diastolic blood pressure \\>100 mmHg); (5) History of non-infectious pneumonia requiring corticosteroid therapy within 1 year before initial dosing, or currently active interstitial lung disease; (6) Significant bleeding disorders or a history of coagulopathy; current or past long-term anticoagulant therapy (e.g., atrial fibrillation with CHADS2 score \\>=2); (7) Active pulmonary tuberculosis; (8) History of inflammatory bowel disease (such as Crohn's disease, ulcerative colitis) or chronic diarrhea; (9) Major surgery or major trauma within 30 days prior to treatment; minor local surgery within 3 days prior to treatment (excluding central venous catheter placement via peripheral vein); (10) Presence of active or uncontrolled infection requiring systemic therapy; (11) Presence of clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction; (12) Uncontrolled comorbidities including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer or gastritis, or mental\u002Fsocial conditions that interfere with protocol compliance or informed consent; (13) Poorly controlled diabetes (fasting blood glucose (FBG) \\>10 mmol\u002FL); (14) Urinalysis indicating proteinuria \\>=++, confirmed by 24-hour urine protein quantification \\>1.0 g.\n* Known history of mental illness, substance abuse, alcoholism, or drug addiction.\n* Any history or evidence of disease that may interfere with the trial results, hinder the subject's full participation in the study, abnormal treatment or laboratory test results, or any other condition that the investigator considers unsuitable for enrollment. The investigator believes that there are other potential risks making the subject unsuitable to participate in this study.\n* Local or systemic diseases caused by tumors, or tumor-related complications with high medical risk or uncertain prognosis (for example, leukocyte response resulting in leukocytes \\>20 × 10\\^9\u002FL, cachexia, weight loss \\>10% in the three months before screening), or BMI \\\u003C=18).",{"count":357,"type":21},146,[89],"This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and meeting the eligibility criteria, enrolled patients will be randomized into two cohorts: Cohort 1 (experimental group) will receive sequential short-course radiotherapy (SCRT) followed by four cycles of SOX plus serplulimab as neoadjuvant therapy prior to surgery; Cohort 2 (control group) will receive four cycles of SOX plus serplulimab as neoadjuvant therapy before surgery. Postoperatively, all patients will continue with four cycles of SOX plus serplulimab as adjuvant therapy, with serplulimab maintained for one year. If patients do not meet the criteria for radical gastrectomy, alternative conservative treatments or surgical approaches will be considered following multidisciplinary team (MDT) discussion. The study aims to evaluate the efficacy and safety of SOX combined with serplulimab, and sequential SCRT followed by SOX plus serplulimab as neoadjuvant therapy leading to radical resection of gastric cancer. All enrolled patients will undergo PD-L1 expression analysis (CPS and TPS scores) and microsatellite instability status (MSI-H population). Where tissue availability and research center conditions permit, exploratory assessments will include minimal residual disease (MRD) measured at baseline, after neoadjuvant therapy, post-surgery, and after adjuvant therapy, tumor mutational burden (TMB), and whole-exome sequencing of tumor tissue. Radiological evaluations will be conducted every 3 months ± 1 week for the first 2 years post-surgery, then every 6 months ± 2 weeks up to 5 years, and annually thereafter until disease recurrence. Survival follow-up will occur every three months after recurrence. Safety visits will span from the first dose to 30 days after the last dose or initiation of new antitumor therapy.",[361],"Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma","2026-06-23",{"date":364,"type":35},"2026-06-29",{"date":258,"type":21},{"date":306,"type":21},{"name":41,"class":42},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":43},"100628592","mindfulness-intervention-on-minimally-invasive-vascular-surgery-100628592","NCT07463638","Mindfulness Intervention on Minimally Invasive Vascular Surgery","Effect of Mindfulness Intervention Based on Virtual Reality Technology on Anxiety and Pain in Minimally Invasive Vascular Surgery Under Local Anesthesia: a Single-center, Prospective, Randomized Controlled Clinical Study","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. ASA physical status classification I-III.\n3. Diagnosis of superficial varicose veins confirmed by clinical examination and imaging studies (e.g., Doppler ultrasound, digital subtraction angiography), with documented venous insufficiency and great saphenous vein varicosity; CEAP classification grade 3-5.\n4. Scheduled for elective minimally invasive surgery for lower extremity varicose veins under local anesthesia.\n5. Voluntary participation in this study with signed informed consent.\n6. Able to cooperate with all examinations and follow-up visits required during the study.\n7. No other severe systemic diseases or surgical contraindications (e.g., severe cardiopulmonary dysfunction, coagulation abnormalities) that may compromise surgical safety or interpretation of study results.\n\nExclusion Criteria:\n\n1. Cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score ≤26).\n2. Inability to wear VR equipment, or presence of sensory impairment (blindness or deafness).\n3. History of the same type of surgery.\n4. Presence of chronic or acute pain unrelated to peripheral vascular disease diagnosis.\n5. Oral opioid or nonsteroidal anti-inflammatory drug (NSAID) use within the past 30 days.\n6. Pregnancy or breastfeeding.\n7. Currently receiving or previously participated in psychological intervention.\n8. Prior mindfulness experience, documented history of psychiatric illness in medical records, or consultation with a trauma psychologist during the current hospitalization.",{"count":376,"type":21},160,[89],"Background: Patients undergoing minimally invasive vascular surgery under local anesthesia often experience significant anxiety and pain, which may compromise surgical outcomes. Virtual reality (VR)-based mindfulness interventions may offer a novel approach to enhance the perioperative experience. Methods: This single-center, prospective randomized controlled trial will enroll 160 patients, randomly assigned in a 1:1 ratio to either the intervention group (VR mindfulness intervention) or the control group (standard care). Primary outcome: State trait anxiety scale (STAI-State) measures anxiety. Secondary outcomes: Numeric Rating Scale (NRS) for pain, vital signs, sleep quality, fatigue levels, satisfaction. Expected Results: VR mindfulness intervention is anticipated to significantly reduce anxiety and pain levels while improving sleep quality, fatigue levels, and patient satisfaction. Conclusion: As a safe, cost-effective, and immersive non-pharmacological intervention, VR mindfulness therapy holds promise for enhancing perioperative care quality.",[380,381],"Anxiety","Pain","2026-06-15",{"date":384,"type":35},"2026-06-17",{"date":386,"type":21},"2026-07",{"date":388,"type":21},"2027-01",{"name":41,"class":42},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":397,"minAge":18,"maxAge":4,"enrollmentInfo":398,"targetDuration":400,"studyType":54,"phases":4,"briefSummary":401,"conditions":402,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":43},"100641814","perioperative-quantitative-sensory-testing-and-incision-pain-mapping-in-thoracic-surgery-100641814","NCT07653932","Perioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery","Perioperative Pain Phenotyping and Incision Pain Mapping Using Quantitative Sensory Testing in Patients Undergoing Thoracoscopic or Robotic-assisted Lung Resection: A Prospective Observational Pilot Cohort Study","Inclusion Criteria:\n\n1. Male\n2. Scheduled to undergo elective thoracoscopic or robotic-assisted lung resection.\n3. American Society of Anesthesiologists physical status I to III.\n4. Able to understand and communicate adequately and to complete study questionnaires independently or with assistance from study staff.\n5. Willing to undergo QST assessment, perioperative venous blood sampling, and postoperative follow-up.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Definite chronic chest wall, shoulder, back, or upper limb pain with an average 2. Numeric Rating Scale score of 3 or higher during the preceding week.\n\n3\\. Definite painful neuropathic disease or long-term use of opioids or other analgesics for more than 2 weeks.\n\n4\\. Peripheral neuropathy, spinal cord disease, or other neurological disease that may substantially interfere with interpretation of QST results.\n\n5\\. Severe cognitive impairment, psychiatric disorder, communication disorder, or inability to complete questionnaires and QST assessments.\n\n6\\. Active infection, active autoimmune disease, or other disease condition that may substantially affect inflammatory protein measurements.\n\n7\\. Emergency surgery, conversion to open thoracotomy, extensive chest wall resection, or severe intraoperative complications.\n\n8\\. Any condition that, in the opinion of the investigator, makes the participant unsuitable for continued participation in the study.","MALE",{"count":399,"type":21},46,"3 Months","Postoperative pain remains a common and clinically important burden after thoracic surgery and may progress to chronic postsurgical pain. Conventional pain assessment mainly relies on patient-reported pain intensity and analgesic consumption, which may not fully capture peri-incisional sensory abnormalities, mechanical hyperalgesia, or central sensitization.\n\nThis prospective observational pilot cohort study aims to evaluate the feasibility and acceptability of perioperative quantitative sensory testing (QST) and incision pain mapping in adult patients undergoing elective thoracoscopic or robotic-assisted lung resection. Participants will undergo baseline assessment before surgery, serial postoperative pain assessments during the first 72 hours, QST and mechanical hyperalgesia pain mapping at 48-72 hours after surgery, and follow-up assessments at discharge, 1 month, and 3 months after surgery.\n\nThe primary feasibility outcomes include recruitment rate, QST completion rates, follow-up completion rates, QST-related discontinuation rate, study-related adverse events, and data completeness. The main clinical mechanistic outcome is the area of peri-incisional mechanical hyperalgesia at 48-72 hours after surgery. Secondary outcomes include acute postoperative pain intensity, pain burden over 72 hours, opioid consumption, quality of recovery, QST changes, pain-map characteristics, and chronic postsurgical pain at 3 months.\n\nThis study will not assign or modify therapeutic interventions. All anesthetic, surgical, and analgesic management will be determined by the routine clinical care team. The study is expected to provide feasibility data, preliminary effect estimates, and mechanistic information for future larger perioperative pain studies.",[403,404,405,406,407,408],"Postoperative Pain","Chronic Postsurgical Pain","Thoracic Surgery","Lung Resection","Mechanical Hyperalgesia","Central Sensitization",[410,411,412,413,414],"Quantitative sensory testing","QST","Incision pain mapping","Thoracoscopic surgery","Perioperative pain phenotype","2026-06-13",{"date":384,"type":35},{"date":418,"type":21},"2026-06-08",{"date":420,"type":21},"2027-02-28",{"name":41,"class":42},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":432,"conditions":433,"keywords":436,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":43},"100642751","wearable-device-based-early-warning-of-postoperative-complications-in-thoracic-surgery-100642751","NCT07646730","Wearable Device-Based Early Warning of Postoperative Complications in Thoracic Surgery","Development and Validation of a Wearable Device-Based Early Warning Model for Postoperative Complications in Thoracic Surgery: A Retrospective and Prospective Cohort Study","wearable","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Hospitalized in the Department of Thoracic Surgery of Tongji Hospital and scheduled to undergo thoracic surgery.\n3. Able to wear the study-designated wearable device after hospital admission and expected to continue wearing the device and\u002For uploading data within 30 days after discharge.\n\nExclusion Criteria:\n\n1. Patients or family members are unwilling to wear the wearable device or unable to meet the required wearing time.\n2. Severe or unstable psychiatric disease, such as severe depression or schizophrenia.\n3. Pregnancy or lactation.\n4. Allergy to the watch strap material or local skin conditions that prevent wearing the device.\n5. Unable to complete follow-up within 30 days after discharge.",{"count":431,"type":21},650,"After thoracic surgery, some patients may develop complications such as lung infection, abnormal heart rhythm, fluid around the lung, prolonged air leak, wound infection, emergency department visits, or hospital readmission. These problems may not be found early if monitoring is only done during routine vital sign checks or follow-up visits.\n\nThis study will evaluate whether data collected by a wearable device can help identify early warning signs of postoperative complications in patients undergoing thoracic surgery. The wearable device will collect information such as heart rate, oxygen level, skin temperature, physical activity, sleep, and wearing status.\n\nThe study includes two parts. First, the researchers will review previously collected wearable device and medical record data to develop an early warning model. Second, new patients undergoing thoracic surgery will wear the device from hospital admission until about 30 days after discharge. The model will then be tested to see how well it predicts complications that require medical intervention within 30 days after surgery.\n\nThe main goal is to evaluate how accurately the wearable device-based model can identify patients who develop postoperative complications and how early the model can provide a warning before the complication is clinically confirmed.",[434,405,435],"Postoperative Complications","Perioperative Monitoring",[437,438,434,405],"Wearable Device","Early Warning Model","2026-06-12",{"date":382,"type":35},{"date":442,"type":35},"2025-12-16",{"date":444,"type":21},"2026-12-15",{"name":41,"class":42},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":270,"studyType":54,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":43},"100637676","prospective-clinical-database-construction-for-liver-cancer-diagnosis-and-treatment-100637676","NCT07587216","Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment","Inclusion Criteria:\n\n* Male or female aged ≥18 years at the time of signing the informed consent form\n* Clinically or histologically confirmed diagnosis of liver cancer\n* Recieving treatment and follow-up in Tongji Hospital\n\nExclusion Criteria:\n\n\\- Refuse participanting in this study",{"count":453,"type":21},800,"This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin",[456],"Liver Cancer (Primary and Metastatic)","2026-06-02",{"date":459,"type":35},"2026-06-04",{"date":461,"type":35},"2026-01-01",{"date":463,"type":21},"2029-12-31",{"name":41,"class":42},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":480,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":493},"100619917","phase-2-a-multicenter-prospective-clinical-trial-with-a-concurrent-control-evaluating-methotrexate-combined-with-rituximabsintilimab-and-pirtobrutinib-vs-investigator-selected-standard-of-care-in-treatment-naive-pcnsl-100619917","NCT07350850","A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL","In Treatment-Naive Patients With Primary Central Nervous System Lymphoma (PCNSL): A Multicenter, Prospective, Concurrent-Control Study of Methotrexate, , Rituximab,, Sintilimab ,Pirtobrutinib Versus Investigator-Selected Standard of Care","PRIME-PCNSL","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Voluntarily signed informed consent.\n3. ECOG Performance Status 0-3.\n4. Expected survival \\> 3 months.\n5. Histopathologically confirmed Diffuse Large B-Cell Lymphoma (DLBCL) restricted to the CNS or eyes (PCNSL).\n6. Measurable lesion on contrast-enhanced MRI (\\>10x10 mm) or positive CSF cytology for leptomeningeal disease.\n7. No prior systemic treatment for lymphoma (corticosteroids excepted).\n8. Adequate bone marrow and organ function (ANC \\>=1.5x10\\^9\u002FL, PLT \\>=80x10\\^9\u002FL, Hb \\>=80 g\u002FL; Bilirubin \\\u003C=1.5xULN, AST\u002FALT \\\u003C=2.5xULN; Creatinine \\\u003C=1.5xULN or CrCl \\>=60 mL\u002Fmin) .\n9. Stable controlled comorbidities allowed (e.g., hypertension with blood pressure \\\u003C=160\u002F100 mmHg, type 2 diabetes with HbA1c \\\u003C=8%, mild coronary heart disease without myocardial infarction in the past 6 months).\n10. Basic communication ability to complete PROs questionnaires (no severe cognitive impairment).\n11. Reproductive-aged females and males with childbearing potential: No pregnancy plans during the study and 3 months after treatment discontinuation; use effective contraception (abstinence, physical contraception, or hormonal contraceptives initiated \\>=3 months before first dose). Males prohibited from donating sperm during treatment and 3 months after discontinuation.\n12. For Observational Cohort (Palliative Care Subgroup only): Pathologically confirmed DLBCL restricted to the CNS or eyes; Follow-up available for efficacy assessment (at least one CR evaluation) .\n\nExclusion Criteria:\n\n1.Prior treatment with PD-1\u002FPD-L1 inhibitors or CTLA4 monoclonal antibodies. Uncontrolled active infection. 2.Uncontrolled or significant cardiovascular diseases: 3.Congestive heart failure (NYHA class III\u002FIV),\n\n1. myocardial infarction, unstable angina within 6 months before first dose; arrhythmia requiring treatment; LVEF \\\u003C50%.\n2. Primary cardiomyopathy.\n3. History of clinically significant QTc prolongation, second-degree type II\u002Fthird-degree atrioventricular block, or QTc interval (Fridericia method) \\>470 msec (females) \u002F \\>480 msec (males).\n4. Atrial fibrillation (EHRA grade ≥2b).\n5. Refractory hypertension. 4.Active hepatitis B\u002FC infection (HBV-DNA ≥ detection limit, HCV RNA positive) or syphilis. (Exceptions: HBV-DNA \\\u003C detection limit, cured HCV).\n\n5.HIV infection. 6.Prior organ transplantation or allogeneic stem cell transplantation. 7.Pregnant or lactating females. 8.Prior\u002Fcurrent pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, or radiation pneumonitis (unsuitable for study per investigator).\n\n9.Autoimmune diseases requiring systemic treatment within 2 years. 10.For Observational Cohort (Palliative Care Subgroup only): Incomplete clinical data (e.g., no pathological report, inability to perform MRI\u002FPET-CT assessment).",{"count":474,"type":21},77,[25],"The goal of this clinical trial is to evaluate the efficacy and safety of a four-drug combination regimen as first-line treatment for adults aged 18 years and older with newly diagnosed primary central nervous system lymphoma (PCNSL). The main questions it aims to answer are:\n\nDoes the combination of pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate achieve a higher complete response rate than standard treatment for newly diagnosed PCNSL? What is the safety and tolerability profile of this four-drug combination regimen? Researchers will compare the experimental four-drug combination to investigator-selected standard-of-care regimens (all based on high-dose methotrexate) to see if the experimental regimen improves complete response rate, progression-free survival, and overall survival while maintaining an acceptable safety profile.\n\nParticipants will:\n\nBe assigned to either the experimental group or the standard treatment group based on their personal preference Receive 6 cycles of induction therapy (21 days per cycle) with their assigned treatment regimen Undergo regular clinical assessments, including contrast-enhanced brain MRI scans, blood tests, and cerebrospinal fluid examinations Complete the EORTC QLQ-C30 quality-of-life questionnaire at baseline, mid-treatment, end of treatment, and follow-up visits Receive optional consolidation or maintenance therapy based on their response to induction treatment Be followed for up to 2 years after completing treatment to monitor for disease progression and long-term outcomes",[478,479],"PCNSL","Primary Central Nervous System Lymphoma",[481,482,483,484,485,486],"Primary Central Nervous System Lymphoma (PCNSL)","Methotrexate","Rituximab","Sintilimab","Pirtobrutinib","Real-World Evidence","2026-05-30",{"date":457,"type":35},{"date":490,"type":35},"2025-12-25",{"date":234,"type":21},{"name":41,"class":42},4,{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":4},"100639839","phase-2-study-on-the-effect-of-oral-diammonium-glycyrrhizinate-in-attenuating-toxicity-and-enhancing-efficacy-of-car-t-cell-therapy-100639839","NCT07616271","Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy","A Single-Center, Prospective, Randomized Controlled Clinical Study of Oral Diammonium Glycyrrhizinate for Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients diagnosed with large B-cell lymphoma and receiving CAR-T cell therapy.\n3. Adequate organ function prior to enrollment: ALT and AST ≤ 2.5 × ULN (upper limit of normal); may be extended to ≤5 × ULN in patients with liver involvement; serum total bilirubin \\\u003C 34 μmol\u002FL; creatinine clearance \\> 30 mL\u002Fmin; cardiac ejection fraction (EF) ≥ 40%, with no pericardial effusion or significant arrhythmia; room air SpO₂ ≥ 92%.\n4. No central nervous system involvement of lymphoma confirmed by MRI prior to enrollment.\n5. Subjects of childbearing potential must agree to use highly effective contraceptive methods.\n6. The subject or their legal guardian must be able to understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Presence of a prior malignancy (other than the disease under study) that requires ongoing systemic treatment for any other malignant tumor.\n2. Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise patient safety or interfere with the interpretation of safety or efficacy data.\n3. Current or prior central nervous system (CNS) involvement by malignancy.\n4. Receipt of allogeneic stem cell transplantation within 6 months prior to enrollment, or autologous stem cell transplantation within 3 months prior to enrollment; and the patient must have no signs or symptoms of graft-versus-host disease and must not be receiving immunosuppressive therapy.\n5. Intolerance or allergy to glycyrrhizic acid preparations.\n6. Patient refuses to comply with the study requirements to complete the research work.\n7. In the investigator's judgment, the patient is unable to complete the study or comply with the study requirements (due to administrative reasons or other reasons), or is considered unsuitable for clinical trial participation for other reasons.",{"count":502,"type":21},21,[25,504],"PHASE3","The purpose of this study is to evaluate the effect of oral diammonium glycyrrhizinate in reducing toxicity and enhancing efficacy of CAR-T cell therapy in patients with large B-cell lymphoma. Two main questions are addressed: 1) Can oral diammonium glycyrrhizinate reduce the incidence and severity of CRS induced by CAR-T cells? 2) Can oral diammonium glycyrrhizinate synergistically increase the therapeutic efficacy of CAR-T cell therapy?",[507],"Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy",[509,510,511,512],"Large B-cell lymphoma","Diammonium Glycyrrhizinate","CAR-T cell therapy","Toxicity reducing and efficacy enhancing","2026-05-29",{"date":515,"type":35},"2026-06-01",{"date":517,"type":21},"2026-05-22",{"date":519,"type":21},"2030-05-31",{"name":41,"class":42},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":554},"100637489","somatostatin-plus-clear-liquid-diet-versus-diverting-stoma-in-patients-with-rectal-cancer-undergoing-ultra-low-anterior-resection-100637489","NCT07605611","Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection","A Multicenter, Randomized Clinical Study of Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Low and Mid Rectal Cancer Undergoing Ultra-Low Anterior Resection","SC-Stoma","Inclusion Criteria:\n\n1. Adults aged 18 to 75 years\n2. Patients with stage I to III rectal malignancy who are scheduled to undergo low anterior resection at a participating gastrointestinal surgery center\n3. The lower edge of the tumor is 8 cm or less from the dentate line, or 10 cm or less from the anal verge, based on preoperative colonoscopy, imaging, or digital rectal examination\n4. The planned anastomosis is expected to be 2 cm or less from the dentate line, or 4 cm or less from the anal verge\n5. Patients have two or more risk factors for anastomotic leakage as assessed by the study team\n6. American Society of Anesthesiologists physical status classification is grade 3 or lower\n7. Body mass index is less than 30 kg\u002Fm²\n8. The patient, or the patient's legally authorized representative, is willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Has another colorectal malignant tumor at the same time\n2. The final anastomosis after surgery is more than 2 cm from the dentate line, or more than 4 cm from the anal verge\n3. Has metastatic disease before surgery\n4. Is pregnant\n5. Has a mental illness or addictive disorder that would prevent participation in the clinical trial\n6. Requires emergency surgery\n7. Has inflammatory bowel disease\n8. Is allergic to somatostatin or is unable to tolerate somatostatin\n9. For participants assigned to the no-stoma group, the surgeon decides that a stoma is required\n10. Has received neoadjuvant drug therapy less than 2 weeks before surgery, or radiotherapy less than 8 weeks before surgery\n11. Has any other condition that makes it impossible to follow the study protocol",{"count":530,"type":21},72,[89],"The goal of this clinical trial is to learn if somatostatin plus a clear liquid diet can help prevent severe leakage after rectal cancer surgery in adults with low or mid rectal cancer who are scheduled to have ultra-low anterior resection. These patients have a higher risk of leakage where the bowel is joined together after surgery.\n\nThe main questions it aims to answer are:\n\nDoes somatostatin plus a clear liquid diet prevent severe leakage within 1 month after surgery about as well as a prophylactic diverting stoma?\n\nWhat medical problems, bowel function problems, recovery outcomes, and quality of life outcomes do participants have after surgery and during follow-up?\n\nResearchers will compare somatostatin plus a clear liquid diet without a diverting stoma to prophylactic diverting stoma to see if the somatostatin plus clear liquid diet regimen can provide similar protection against severe leakage while reducing the need for stoma creation.\n\nParticipants will:\n\nHave rectal cancer surgery with the bowel joined very close to the anus\n\nBe randomly assigned to receive either somatostatin plus a clear liquid diet for 7 days after surgery without a diverting stoma, or a prophylactic diverting stoma\n\nHave follow-up assessments of leakage, postoperative complications, bowel function, recovery quality, and quality of life\n\nComplete follow-up visits or assessments for up to 3 years after surgery",[534,535],"Rectal Cancer","Anastomotic Leakage",[537,538,539,540,541,542,543,544,545,546],"Rectal cancer","Ultra-low anterior resection","Anastomotic leakage","Severe anastomotic leakage","Diverting stoma","Prophylactic stoma","Somatostatin","Clear liquid diet","Bowel function","Quality of life",{"date":548,"type":35},"2026-05-26",{"date":550,"type":35},"2025-11-17",{"date":552,"type":21},"2030-06-30",{"name":41,"class":42},3,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":561,"minAge":562,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":554},"100639265","phase-4-clinical-efficacy-study-of-jinfeng-pill-in-the-treatment-of-perimenopausal-syndrome-100639265","NCT07606755","Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome","Inclusion Criteria:\n\n1. Female patients aged 45-55 years;\n2. Menstrual disorders (prolonged menstrual cycle or hypomenorrhea) lasting for more than 3 months, or amenorrhea for 2-12 months;\n3. Presence of vasomotor symptoms (hot flashes, sweating), somatic symptoms (insomnia, fatigue, headache, paresthesia), psychological symptoms (anxiety, depression), or urogenital symptoms (dyspareunia, vaginal dryness, urinary tract infection);\n4. Serum follicle-stimulating hormone (FSH) \\> 10 IU\u002FL, or decreased estradiol (E2) levels;\n5. No use of HRT or other medications for perimenopausal symptoms in the past 2 months;\n6. Intact uterus and bilateral adnexa, not surgically removed;\n7. Voluntary participation and signing of informed consent;\n8. Modified Kupperman Index (KI score) ≥ 6, indicating mild or above symptoms.\n\nExclusion Criteria:\n\n1. Does not meet the inclusion criteria listed above;\n2. Ovarian malignancy, ovarian or hysterectomy, premature ovarian failure, uterine fibroids ≥2 cm, severe breast hyperplasia;\n3. Acute gynecological infectious diseases or other acute infectious diseases;\n4. Severe liver or kidney dysfunction, or other serious systemic diseases;\n5. Use of hormonal drugs or traditional Chinese medicine for treatment in the past 2 months;\n6. Participation in other clinical trials;\n7. Patients who did not adhere to the treatment protocol or withdrew from the trial;","FEMALE","45 Years","55 Years",{"count":565,"type":21},100,[567],"PHASE4","Perimenopausal syndrome (PMS) is a common condition affecting women during the transition to menopause, often causing hot flashes, sweating, insomnia, anxiety, depression, fatigue, and reduced quality of life. Current hormone replacement therapy can improve symptoms, but long-term use may increase the risk of breast cancer and cardiovascular complications. Therefore, safer and more effective alternative treatments are needed.\n\nJinfeng Pill is a traditional Chinese medicine patented drug that has been widely used in gynecological disorders. Previous studies suggest that it may help regulate hormone balance, improve ovarian function, and reduce inflammation. Recent research has also shown that intestinal bacteria (\"gut microbiota\") may influence estrogen metabolism through the \"gut microbiota-estrogen axis,\" which could play an important role in perimenopausal symptoms.\n\nThis study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness and safety of Jinfeng Pill in women with perimenopausal syndrome. Eligible participants will be randomly assigned to receive either Jinfeng Pill or a placebo for 12 weeks. Researchers will assess changes in menopausal symptoms, mood, sleep, and quality of life using standardized questionnaires and laboratory tests.\n\nIn addition, the study will explore how Jinfeng Pill may regulate gut microbiota, β-glucuronidase (β-GUS) activity, short-chain fatty acids (SCFAs), inflammatory factors, and estrogen-related indicators. The findings may provide new evidence for the clinical use of traditional Chinese medicine in the treatment of perimenopausal syndrome and help clarify its underlying biological mechanisms.",[570],"Perimenopausal Syndrome",[570,572],"Jinfeng Pill","2026-05-18",{"date":548,"type":35},{"date":576,"type":21},"2026-05-10",{"date":578,"type":21},"2028-05-01",{"name":41,"class":42},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":294,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":43},"100633285","a-study-about-remote-and-local-liver-surgery-100633285","NCT07524699","A Study About Remote and Local Liver Surgery","Efficacy and Safety of MP1000 System in Remote and Local Liver Surgery: A Prospective, Multicenter, Single-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age range: 18-75 years old (inclusive), gender not restricted;\n2. BMI: 18-30 Kg\u002Fm2;\n3. Relevant indications for liver surgery;\n4. Physiological condition allows for laparoscopic surgery, and the Iwate score for laparoscopic difficulty of the enrolled patients is ≤ 6;\n5. Willing to cooperate and complete follow-up and related subsequent examinations;\n6. Voluntary to sign the informed consent form;\n7. Indocyanine green 15-minute retention rate (ICG-R15) \\\u003C 15%, and liver function Child-Pugh grade is A.\n\nExclusion Criteria:\n\n1. Patients with severe circulatory system diseases who cannot tolerate surgery;\n2. Pregnant or lactating women;\n3. Patients with a history of epilepsy or mental illness;\n4. Patients with severe allergic constitution and those suspected or diagnosed with alcohol or drug addiction;\n5. Patients who cannot understand the research requirements or who cannot complete the research follow-up;\n6. Patients considered unsuitable to participate in this trial by the researchers.",{"count":588,"type":21},148,[89],"The goal of this clinical trial is to learn if the robotic surgical system producted by Shenzhen Edge Medical Company has a non-inferior textbook outcome in liver surgery in the field of remote surgery compared to local robotic surgery. It will also learn about the safety of remote liver surgery.\n\nThe main questions are: Does remote liver surgery not lower the textbook outcomes in liver surgery compared to the local robotic surgery? What complications do participants have when taking remote liver surgery? Investigators will compare remote liver surgery to local robotic liver surgery to see if remote liver surgery doesn't lower the textbook outcome in liver surgery.\n\nParticipants will:\n\nUndergo remote or local robotic liver surgery according to the random program; Visit the clinic in 3, 28 and 42 day after surgery for checkups and tests; Keep a diary of their postoperative complications.",[592],"Liver Diseases",[594,595,596],"Remote Surgery","Liver Surgery","Randomized controlled trial","2026-05-13",{"date":573,"type":35},{"date":600,"type":21},"2026-05-16",{"date":602,"type":21},"2028-07-31",{"name":41,"class":42},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":561,"minAge":18,"maxAge":294,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":43},"100593123","phase-3-invigorate-a-study-of-ql1706-and-bevacizumab-in-advanced-first-line-ovarian-clear-cell-carcinoma-100593123","NCT07002346","INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma","A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Trial Evaluating QL1706 With Bevacizumab Versus Standard Platinum-Based Chemotherapy With or Without Bevacizumab as First-line Treatment for Advanced Ovarian Clear Cell Carcinoma","INVIGORATE","Inclusion Criteria:\n\n* Voluntary participation in the study and signed informed consent form.\n* Age ≥ 18 years and \\\u003C 75 years, female.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival ≥ 3 months.\n* Histologically or cytologically newly diagnosed FIGO stage IC-IV ovarian clear cell carcinoma.\n* Patients are planned to undergo primary debulking surgery (PDS), regardless of whether satisfactory debulking is achieved, and have complete surgical records and residual disease assessment results (R0 vs R1\u002FR2).\n* No prior first-line postoperative systemic antitumor therapy for the current ovarian clear cell carcinoma, including chemotherapy, targeted therapy, immunotherapy, etc.\n* Adequate organ function confirmed by the following requirements:\n\nHematological (no use of any blood components or cell growth factors within 7 days prior to initiation of study treatment):\n\ni. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL (1,500\u002Fmm\\^3). ii. Platelet count ≥ 100 × 10\\^9\u002FL (100,000\u002Fmm\\^3). iii. Hemoglobin ≥ 90 g\u002FL.\n\nRenal:\n\ni. Calculated creatinine clearance (CrCl) ≥ 50 mL\u002Fmin. CrCl will be calculated using the Cockcroft-Gault formula: CrCl (mL\u002Fmin) = \\[(140 - age) × weight (kg) × F\\] \u002F \\[SCr (mg\u002FdL) × 72\\], where F = 0.85 for females and SCr = serum creatinine.\n\nii. Urine protein \\\u003C 2+ or 24-hour quantitative urine protein \\\u003C 1.0 g.\n\nHepatic:\n\ni. Total serum bilirubin (TBil) ≤ 1.5 × ULN. ii. AST and ALT ≤ 2.5 × ULN.\n\nCoagulation:\n\ni. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n\n\\- For women of childbearing potential, a negative serum or urine pregnancy test within one week prior to enrollment, and effective contraceptive measures must be used after enrollment, for example, use of physical barrier contraception (condoms) or complete abstinence. Oral, injectable, or implantable hormonal contraceptives are not permitted. Or, women of non-childbearing potential, defined as: i. Naturally postmenopausal for at least 1 year. ii. Surgically sterile, including bilateral oophorectomy, bilateral salpingectomy, or hysterectomy.\n\niii. Serum follicle-stimulating hormone, luteinizing hormone, and plasma estradiol levels within the postmenopausal range for the study center's laboratory.\n\n* Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study requirements.\n* Patient is willing to cooperate in completing quality of life questionnaires during the trial treatment and follow-up period, and agrees that these questionnaire results can be used for clinical research.\n\nExclusion Criteria:\n\n* Histologically confirmed ovarian cancer of other epithelial origin or non-epithelial origin, other than ovarian clear cell carcinoma; ovarian tumors of low malignant potential, such as borderline tumors.\n* Prior systemic preoperative antitumor therapy for the current ovarian clear cell carcinoma, including but not limited to neoadjuvant chemotherapy (NACT) or other types of neoadjuvant therapy, or planned neoadjuvant therapy followed by interval debulking surgery (IDS) during screening.\n* Prior treatment with immune checkpoint inhibitors, such as PD-1\u002FPD-L1 antibodies, or drugs targeting other T-cell receptors, such as CTLA-4, as well as immune checkpoint agonist antibodies, such as anti-ICOS, CD40, CD137, GITR, or OX40 antibodies, and immune cell therapy.\n* Systemic use of corticosteroids or other immunosuppressive drugs, such as cyclophosphamide, azathioprine, methotrexate, thalidomide, or TNFα inhibitors, within 2 weeks before the first dose. Note: Inhaled or topical steroids, steroids as premedication for hypersensitivity reactions, such as CT scan contrast agent premedication or cytotoxic chemotherapy premedication, or adrenal replacement steroids, daily ≤10 mg prednisone or equivalent, are permitted in the absence of active autoimmune disease.\n* Prior, within 5 years, or concurrent malignancies, with the exception of cured local tumors, such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, etc., and breast cancer with no recurrence \\>3 years after radical surgery.\n* Patients with contraindications to bevacizumab, including but not limited to prior gastrointestinal perforation, surgery within 28 days before medication or incompletely healed wounds, severe bleeding or recent hemoptysis, or other situations where the investigator deems bevacizumab unsuitable.\n* Receipt of live vaccine within 30 days before the first dose of study treatment, persisting until 90 days after the last dose of study treatment. Note: Live vaccines include but are not limited to measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza virus vaccines not containing live virus, inactivated COVID-19 vaccines, etc., are permitted.\n* Active autoimmune disease requiring systemic treatment, such as use of disease-modifying drugs, corticosteroids, or immunosuppressants, within 2 years before the first dose. Replacement therapies, such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency, are not considered systemic treatment. Note: Patients with cataracts, Graves' disease, or psoriasis not requiring systemic treatment within the past 2 years are not excluded.\n* Systemic infection requiring systemic antibiotic treatment or other severe infections within 2 weeks before randomization, or unexplained fever \\>38.0°C during the screening period or before enrollment, and inability to discontinue aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) for more than 5 days.\n* Severe illness or concomitant non-tumor diseases, such as neurological disorders, psychiatric disorders, infectious diseases, or laboratory abnormalities, that may increase the risk of participating in the study or taking study drugs, and which the investigator deems would make the patient unsuitable for the study.\n* Pregnant or lactating women.\n* Clinically significant cardiovascular diseases, including but not limited to:\n\n  1. Myocardial infarction or unstable angina within 6 months before the first dose.\n  2. Stroke or transient ischemic attack within 6 months before the first dose.\n  3. Hypertension not controlled by optimal antihypertensive therapy, defined as systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg.\n  4. Poorly controlled arrhythmias. Patients who have stabilized before the first dose and have been stable for ≥14 days may be enrolled.\n  5. Congestive heart failure, New York Heart Association (NYHA) functional class II-IV.\n  6. Myocarditis.\n* Expectation of needing any other form of anti-tumor therapy during the study period.\n* Receipt of traditional Chinese medicines with anti-tumor indications or immunomodulatory drugs, including but not limited to thymosin, interferon, interleukin-2, etc., within 2 weeks before the first dose.\n* HIV-positive patients.\n* Known history of anti-tuberculosis treatment within one year before the first administration of study treatment.\n* Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) ≥2000 IU\u002FmL or 10\\^4 copies\u002FmL; HCV antibody positive and HCV RNA positive.\n* Pre-existing peripheral neuropathy of grade ≥2 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\n* Current or recent, within 10 days before the first dose of study drug, continuous use of full-dose oral or parenteral anticoagulants or thrombolytic agents for 10 days. Note: Prophylactic use of low-dose anticoagulants is permitted, including low-dose warfarin (≤1 mg\u002Fday), low-dose heparin (≤12,000 U\u002Fday), or low-dose aspirin (≤100 mg\u002Fday), provided the prothrombin time international normalized ratio (INR) is ≤1.5.\n* Hereditary bleeding tendency or coagulation dysfunction, or history of thrombosis, or imaging showing tumor invasion\u002Finfiltration of major blood vessels, or investigator or radiologist assessment of bleeding tendency.\n* Known history of severe allergy to macromolecular protein preparations, or to any component of QL1706 or other investigational drugs, or severe allergic history to chemotherapeutic drugs such as carboplatin, paclitaxel, nab-paclitaxel, or their premedications.\n* Currently participating in interventional clinical research treatment, or receiving any other investigational drug or research device treatment within 4 weeks before the first dose. Patients who failed screening for other clinical trials may be included in this study.\n* Patients deemed unsuitable for participation in this study by the investigator.",{"count":613,"type":21},226,[504],"The goal of this phase 3 clinical trial is to evaluate whether QL1706 plus bevacizumab can effectively treat adult female patients (18 to \\\u003C75 years old) with newly diagnosed FIGO stage IC-IV ovarian clear cell carcinoma. The main questions it aims to answer are:\n\n1. Does QL1706 plus bevacizumab, compared with standard platinum-based chemotherapy with or without bevacizumab, prolong patients' progression-free survival (PFS)?\n2. What is the safety profile of QL1706 followed by QL1706 plus bevacizumab, such as what medical problems (adverse events) do participants experience?\n\nResearchers will compare QL1706 followed by QL1706 plus bevacizumab (experimental arm) with standard platinum-based chemotherapy consisting of paclitaxel plus carboplatin with or without bevacizumab (control arm) to see whether QL1706-based immunotherapy is more effective in the first-line treatment of advanced ovarian clear cell carcinoma.\n\nParticipants will:\n\n1. Be randomly assigned to receive either QL1706 alone during Cycle 1 followed by QL1706 plus bevacizumab from Cycle 2, or paclitaxel plus carboplatin with or without bevacizumab according to prespecified high-risk criteria.\n2. Visit the research center regularly for drug infusions, medical examinations (such as vital signs, physical exams, laboratory tests), and tumor imaging assessments.\n3. Complete quality of life questionnaires as required.",[617],"Ovarian Clear Cell Carcinoma",[617,619,620,621,622],"QL1706","Bevacizumab","First-line treatment","Immunotherapy",{"date":573,"type":35},{"date":625,"type":35},"2025-11-15",{"date":627,"type":21},"2029-06-01",{"name":41,"class":42},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":561,"minAge":4,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":638,"conditions":639,"keywords":643,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":43},"100638338","prospective-sample-collection-study-for-a-blood-based-cfdna-methylation-assay-for-ovarian-cancer-detection-100638338","NCT07593833","Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection","Prospective Clinical Validation Study of a Blood-Based cfDNA Methylation Assay for the Detection of Ovarian Cancer","Inclusion Criteria:\n\n* Female participants.\n* Participants with an ovarian\u002Fadnexal mass who are planned to undergo, for the first time at the current center, surgery or biopsy\u002Fpathologic sampling related to the current lesion, with an expected pathologic diagnosis available as the reference standard.\n* Imaging evaluation during screening suggests a unilateral or bilateral, unilocular or multilocular cystic-solid or solid ovarian\u002Fadnexal mass requiring differential diagnosis.\n* An adequate peripheral blood sample can be collected before the first surgery or before initiation of any systemic anti-tumor treatment for the current ovarian\u002Fadnexal mass, and the sample can be processed and stored within the required time according to the unified study procedures.\n* Clinical data and postoperative pathologic results are expected to be sufficiently complete to provide key information for subsequent analyses.\n* The participant or her legally authorized representative voluntarily signs written informed consent after being fully informed.\n\nExclusion Criteria:\n\n* The participant has already received systemic anti-tumor treatment for the current ovarian\u002Fadnexal lesion under evaluation, such as chemotherapy, targeted therapy, immunotherapy, or radiotherapy, or has already undergone definitive tumor resection or comprehensive staging surgery, and is undergoing surgery only for residual or recurrent lesions.\n* No pathologic diagnosis is ultimately obtained for the current ovarian\u002Fadnexal mass, or no analyzable pathologic conclusion can be established.\n* Imaging findings at screening are highly typical of benign mature cystic teratoma.\n* Ovarian cancer combined with another malignant tumor.\n* There are obvious noncompliances during sample collection, transport, or processing, resulting in severe hemolysis, contamination, or seriously insufficient sample volume, such that the sample cannot meet quality control requirements for cfDNA methylation testing or subsequent analyses.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.",{"count":637,"type":21},1000,"The goal of this observational study is to learn whether a blood-based cell-free DNA (cfDNA) methylation assay can help detect ovarian cancer, especially early-stage ovarian cancer, in women undergoing clinical evaluation for ovarian tumors or gynecologic diseases. The main questions it aims to answer are:\n\nHow well can this assay distinguish ovarian cancer from benign gynecologic diseases? How accurately can this assay detect early-stage ovarian cancer and other ovarian tumor subtypes?\n\nResearchers will compare the test results from participants with ovarian cancer and participants with benign gynecologic diseases to evaluate the diagnostic performance of the assay.\n\nParticipants will:\n\nProvide blood samples for cfDNA methylation testing Allow researchers to collect clinical and pathological information related to their diagnosis Be grouped according to their final clinical or pathological diagnosis for analysis",[640,641,642],"Ovarian Neoplasms","Ovarian Cancer","Early Detection of Cancer",[641,640,644,645,646,647,648,649,147,650,651,652],"cfDNA Methylation","Cell-Free DNA","DNA Methylation","Liquid Biopsy","Blood-Based Assay","Early Detection","Early Diagnosis","Diagnostic Performance","Ovarian Tumor","2026-05-12",{"date":573,"type":35},{"date":304,"type":21},{"date":657,"type":21},"2029-12-30",{"name":41,"class":42},""]